½ÃÀ庸°í¼­
»óǰÄÚµå
1620822

ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå : Á¦Ç°, °ø±Þ¿ø, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Recombinant Cell Culture Supplements Market by Product (Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors), Source (Animals, Human), Application, End-use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀçÁ¶ÇÕ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀº 2023³â 6¾ï 8,877¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 7¾ï 8,431¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 14.37% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 17¾ï 6,346¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦´Â ¹è¾ç ¼¼Æ÷ÀÇ ¼ºÀå, »ý»ê¼º, »ýÁ¸À²À» ³ôÀ̱â À§ÇØ »ç¿ëµÇ´Â Çʼö ¼ººÐÀ̸ç, Á¾·¡ÀÇ µ¿¹° À¯·¡ Á¦Ç° ´ë½Å¿¡ ÀçÁ¶ÇÕ DNA ±â¼ú·ÎºÎÅÍ ¼³°èµÈ °ÍÀÌ »ç¿ëµË´Ï´Ù. ±× Çʿ伺Àº ¹ÙÀÌ¿À ÀǾàǰ, ¹é½Å, Àç»ý ÀÇ·á¿¡¼­ º¸´Ù ¾ÈÀüÇϰí Àϰü¼º ÀÖ°í È®Àå °¡´ÉÇÑ ÇÁ·Î¼¼½º¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ º¸ÃæÁ¦´Â Æ÷À¯·ù, °ïÃæ, ½Ä¹°ÀÇ ¼¼Æ÷ ¹è¾ç¿¡ ÀÀ¿ëµÇ°í, Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, Çмú¿¬±¸ µî ÃÖÁ¾ ¿ëµµ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. ½Ã Dz, µ¿¹° À¯·¡ ¼ººÐÀÇ ¸®½ºÅ© Àú°¨ÀÌ ´õ¿í ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °¡ ÇÏÁö¸¸ ½ÃÀå ¼ºÀåÀÇ °úÁ¦·Î´Â Á¦Á¶ ºñ¿ëÀÇ ³ôÀÌ, ±ÔÁ¦ »óȲÀÇ ¾ö°ÝÇÔ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÎÁöµµ¿Í ä¿ë·üÀÇ ³·À½À» µé ¼ö ÀÖ½À´Ï´Ù., °ü¹Î ÆÄÆ®³Ê½Ê È«º¸ µû¶ó¼­ ¿¬±¸ °³¹ß ´É·Â°ú ½ÃÀå ħÅõ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. Çâ»ó °¡´É ¶ÇÇÑ, ƯÁ¤ ¼¼Æ÷¿Í Ä¡·áÀÇ ¿ä±¸¿¡ ¸Â´Â º¸ÃæÁ¦ÀÇ ³óµµ¿Í Á¶ÇÕÀ» ÃÖÀûÈ­ÇÏ´Â ¿¬±¸´Â È¿À²¼º°ú Á¦Ç° ǰÁú¿¡ ȹ±âÀûÀÎ Áøº¸¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù.¿¡¼­ °æÀï ÇÕÀÇ »óŰ¡ °è¼ÓµÇ°í ÀÖÀ¸¸ç, ÁøÈ­ÇÏ´Â ¾÷°è ¿ä°Ç, ±ÔÁ¦ ±âÁØ, ±â¼úÀÇ Áøº¸¿¡ ´ëÀÀÇϱâ À§ÇÑ Çõ½ÅÀÌ ²÷ÀÓ¾øÀÌ ¿ä±¸µÇ°í Àֱ⠶§¹®¿¡ ±â¾÷Àº ¹Ì·¡ÀÇ ¼ºÀå ±âȸ¸¦ »ì¸®±â À§ÇØ ¹ÎøÇÏ°í ±àÁ¤ÀûÀÎ ÀÚ¼¼¸¦ À¯ÁöÇÑ´Ù °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 6¾ï 8,877¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 7¾ï 8,431¸¸ ´Þ·¯
¿¹Ãø³â(2030) 17¾ï 6,346¸¸ ´Þ·¯
CAGR(%) 14.37%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è Á¾¾çÇÐ ¹× Áٱ⼼Æ÷ ¿¬±¸ÀÇ È°¼ºÈ­
    • ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Á¤Ã¥
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ °ü·Ã ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • ½Å±Ô ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ µµÀÔ Áõ°¡
    • 3D ¼¼Æ÷ ¹è¾ç ±â¼ú¿¡ ´ëÇÑ Å½±¸ Áõ°¡
  • ½ÃÀå °úÁ¦
    • ºÐ¼® ±â¼ú°ú 3D ¼¼Æ÷ ¹è¾çÀÇ ºñȣȯ¼º

Porter's Five Forces: ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀçÁ¶ÇÕ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀçÁ¶ÇÕ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀçÁ¶ÇÕ ¼¼Æ÷ ¹è¾ç º¸ÃæÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå : Á¦Ç°º°

    • ÀçÁ¶ÇÕ ¾ËºÎ¹Î
    • ÀçÁ¶ÇÕ ¾ÆÇÁ·ÎƼ´Ñ
    • ÀçÁ¶ÇÕ ¼ºÀå ÀÎÀÚ
    • ÀçÁ¶ÇÕ Àν¶¸°
    • ÀçÁ¶ÇÕ ¸®¼ÒÀÚÀÓ
    • ÀçÁ¶ÇÕ Æ®·£½ºÆä¸°
    • ÀçÁ¶ÇÕ Æ®¸³½Å

    Á¦7Àå ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå : ¼Ò½ºº°

    • µ¿¹°
    • Àΰ£

    Á¦8Àå ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå : ¿ëµµº°

    • À¯ÀüÀÚ Ä¡·á
    • Áٱ⼼Æ÷¿ä¹ý
    • ¹é½Å °³¹ß

    Á¦9Àå ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

    • Çмú¿¬±¸±â°ü
    • ¹ÙÀÌ¿ÀÀǾàǰ±â¾÷
    • °è¾à ¿¬±¸¼¾ÅÍ(CRO)

    Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀçÁ¶ÇÕ ¼¼Æ÷¹è¾ç º¸ÃæÁ¦ ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦13Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • Abcam PLC
    • Becton, Dickinson and Company
    • Bio-Techne Corporation
    • BPS Bioscience, Inc.
    • Cell Sciences, Inc.
    • Cytiva
    • F. Hoffmann-La Roche Ltd.
    • FUJIFILM Corporation
    • HiMedia Laboratories Pvt Ltd
    • InVitria
    • Kerry Group PLC
    • Kingfisher Biotech, Inc.
    • Laurus Labs Limited
    • Lonza Group Ltd.
    • Merck KGaA
    • Novo Nordisk A/S
    • Novozymes A/S
    • PELOBIOTECH GmbH
    • Repligen Corporation
    • Sartorius AG
    • STEMCELL Technologies
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • Zhuhai Gene-Biocon Biological Technology Co., Ltd.
    BJH 25.01.08

    The Recombinant Cell Culture Supplements Market was valued at USD 688.77 million in 2023, expected to reach USD 784.31 million in 2024, and is projected to grow at a CAGR of 14.37%, to USD 1,763.46 million by 2030.

    Recombinant cell culture supplements are essential components used to enhance the growth, productivity, and survival of cells in culture, replacing traditional animal-derived products with those engineered from recombinant DNA technology. Their necessity arises from the growing demand for safer, more consistent, and scalable processes in biopharmaceuticals, vaccines, and regenerative medicine, where animal serum alternatives are critical due to the risk of contamination and ethical concerns. These supplements find applications in mammalian, insect, and plant cell cultures, expanding the end-use scope across pharmaceuticals, biotechnology, and academic research. Market growth is primarily driven by advancements in biotechnology, the surge in R&D investments, and increasing adoption of bioproduction systems. The shift towards personalized medicine and biologics as well as the emphasis on reducing animal-derived component risks further fuel demand. Recent potential opportunities include expanding applications in stem cell research and regenerative therapies, along with innovation in supplement formulations tailored for emerging cell line technologies. Nevertheless, market growth is challenged by high costs of production, stringent regulatory landscapes, and limited awareness or adoption in emerging markets. To overcome these limitations, fostering public-private partnerships could enhance R&D capabilities and market penetration. Innovations in synthetic biology and microfluidics present significant opportunities for businesses to leverage cutting-edge technologies, enabling precise supplement formulation and enhanced cell viability. Additionally, research into optimizing supplement concentrations and combinations tailored to specific cell and therapeutic needs can lead to breakthroughs in efficiency and output quality. The market remains dynamic and competitive, with a continual need for innovation to address evolving industry requirements, regulatory standards, and technological advancements, making it essential for businesses to remain agile and forward-thinking to capitalize on future growth opportunities.

    KEY MARKET STATISTICS
    Base Year [2023] USD 688.77 million
    Estimated Year [2024] USD 784.31 million
    Forecast Year [2030] USD 1,763.46 million
    CAGR (%) 14.37%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Recombinant Cell Culture Supplements Market

    The Recombinant Cell Culture Supplements Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Growing oncology and stem cell research activities globally
      • Supportive government initiatives for biosimilar and biologics products
    • Market Restraints
      • High cost associated with recombinant cell culture supplements
    • Market Opportunities
      • Rising introduction of novel recombinant cell culture supplements
      • Growing exploration of 3D cell culture technologies
    • Market Challenges
      • Incompatibilities of analytical technologies with 3D cell culture

    Porter's Five Forces: A Strategic Tool for Navigating the Recombinant Cell Culture Supplements Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Recombinant Cell Culture Supplements Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Recombinant Cell Culture Supplements Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Recombinant Cell Culture Supplements Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Recombinant Cell Culture Supplements Market

    A detailed market share analysis in the Recombinant Cell Culture Supplements Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Recombinant Cell Culture Supplements Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Recombinant Cell Culture Supplements Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Recombinant Cell Culture Supplements Market

    A strategic analysis of the Recombinant Cell Culture Supplements Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Recombinant Cell Culture Supplements Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Becton, Dickinson and Company, Bio-Techne Corporation, BPS Bioscience, Inc., Cell Sciences, Inc., Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, HiMedia Laboratories Pvt Ltd, InVitria, Kerry Group PLC, Kingfisher Biotech, Inc., Laurus Labs Limited, Lonza Group Ltd., Merck KGaA, Novo Nordisk A/S, Novozymes A/S, PELOBIOTECH GmbH, Repligen Corporation, Sartorius AG, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., and Zhuhai Gene-Biocon Biological Technology Co., Ltd..

    Market Segmentation & Coverage

    This research report categorizes the Recombinant Cell Culture Supplements Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Product, market is studied across Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors, Recombinant Insulin, Recombinant Lysozyme, Recombinant Transferrin, and Recombinant Trypsin.
    • Based on Source, market is studied across Animals and Human.
    • Based on Application, market is studied across Gene Therapy, Stem Cell Therapy, and Vaccine Development.
    • Based on End-use, market is studied across Academic & Research Institutes, Biopharmaceutical Companies, and Contract Research Centers (CROs).
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Growing oncology and stem cell research activities globally
        • 5.1.1.2. Supportive government initiatives for biosimilar and biologics products
      • 5.1.2. Restraints
        • 5.1.2.1. High cost associated with recombinant cell culture supplements
      • 5.1.3. Opportunities
        • 5.1.3.1. Rising introduction of novel recombinant cell culture supplements
        • 5.1.3.2. Growing exploration of 3D cell culture technologies
      • 5.1.4. Challenges
        • 5.1.4.1. Incompatibilities of analytical technologies with 3D cell culture
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Product: Increasing utilization of recombinant albumin for the production of vaccines and therapeutic proteins
      • 5.2.2. End-use: Ongoing research & development activities academic and research institutes boosts the demand of recombinant cell culture supplements
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Recombinant Cell Culture Supplements Market, by Product

    • 6.1. Introduction
    • 6.2. Recombinant Albumin
    • 6.3. Recombinant Aprotinin
    • 6.4. Recombinant Growth Factors
    • 6.5. Recombinant Insulin
    • 6.6. Recombinant Lysozyme
    • 6.7. Recombinant Transferrin
    • 6.8. Recombinant Trypsin

    7. Recombinant Cell Culture Supplements Market, by Source

    • 7.1. Introduction
    • 7.2. Animals
    • 7.3. Human

    8. Recombinant Cell Culture Supplements Market, by Application

    • 8.1. Introduction
    • 8.2. Gene Therapy
    • 8.3. Stem Cell Therapy
    • 8.4. Vaccine Development

    9. Recombinant Cell Culture Supplements Market, by End-use

    • 9.1. Introduction
    • 9.2. Academic & Research Institutes
    • 9.3. Biopharmaceutical Companies
    • 9.4. Contract Research Centers (CROs)

    10. Americas Recombinant Cell Culture Supplements Market

    • 10.1. Introduction
    • 10.2. Argentina
    • 10.3. Brazil
    • 10.4. Canada
    • 10.5. Mexico
    • 10.6. United States

    11. Asia-Pacific Recombinant Cell Culture Supplements Market

    • 11.1. Introduction
    • 11.2. Australia
    • 11.3. China
    • 11.4. India
    • 11.5. Indonesia
    • 11.6. Japan
    • 11.7. Malaysia
    • 11.8. Philippines
    • 11.9. Singapore
    • 11.10. South Korea
    • 11.11. Taiwan
    • 11.12. Thailand
    • 11.13. Vietnam

    12. Europe, Middle East & Africa Recombinant Cell Culture Supplements Market

    • 12.1. Introduction
    • 12.2. Denmark
    • 12.3. Egypt
    • 12.4. Finland
    • 12.5. France
    • 12.6. Germany
    • 12.7. Israel
    • 12.8. Italy
    • 12.9. Netherlands
    • 12.10. Nigeria
    • 12.11. Norway
    • 12.12. Poland
    • 12.13. Qatar
    • 12.14. Russia
    • 12.15. Saudi Arabia
    • 12.16. South Africa
    • 12.17. Spain
    • 12.18. Sweden
    • 12.19. Switzerland
    • 12.20. Turkey
    • 12.21. United Arab Emirates
    • 12.22. United Kingdom

    13. Competitive Landscape

    • 13.1. Market Share Analysis, 2023
    • 13.2. FPNV Positioning Matrix, 2023
    • 13.3. Competitive Scenario Analysis
      • 13.3.1. Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
      • 13.3.2. Albumedix and Heartseed announce Recombumin as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences
    • 13.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Abcam PLC
    • 2. Becton, Dickinson and Company
    • 3. Bio-Techne Corporation
    • 4. BPS Bioscience, Inc.
    • 5. Cell Sciences, Inc.
    • 6. Cytiva
    • 7. F. Hoffmann-La Roche Ltd.
    • 8. FUJIFILM Corporation
    • 9. HiMedia Laboratories Pvt Ltd
    • 10. InVitria
    • 11. Kerry Group PLC
    • 12. Kingfisher Biotech, Inc.
    • 13. Laurus Labs Limited
    • 14. Lonza Group Ltd.
    • 15. Merck KGaA
    • 16. Novo Nordisk A/S
    • 17. Novozymes A/S
    • 18. PELOBIOTECH GmbH
    • 19. Repligen Corporation
    • 20. Sartorius AG
    • 21. STEMCELL Technologies
    • 22. Takara Bio Inc.
    • 23. Thermo Fisher Scientific Inc.
    • 24. Zhuhai Gene-Biocon Biological Technology Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦